Opinion|Videos|January 5, 2026
Exploring Triplet Therapies in IDH-Mutated AML
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss data from MD Anderson Cancer Center on triplet therapies in AML with IDH mutations.
Advertisement
Episodes in this series
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, review data from a study published at The University of Texas MD Anderson Cancer Center evaluating triplet therapy approaches in patients with IDH-mutated acute myeloid leukemia (AML). They discuss early efficacy signals, response depth, and tolerability observed with combinations incorporating IDH inhibitors. DiNardo and Altman place these findings in context of evolving treatment paradigms for molecularly defined AML subsets.
Advertisement
Related to this article
A pilot study represents a milestone toward testing a faster, more powerful, and potentially less-toxic form of radiation therapy for cancer treatment.
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
UTRxMYCN M1-14 received orphan drug status for soft tissue sarcoma and RPDD for rhabdomyosarcoma.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Plinabulin Plus Docetaxel in Post-ICI Non-Squamous NSCLC
2
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
3
Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape
4
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
5